Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy.

Raymond ChangUmberto TosiJulia VoroninaOluwaseyi AdeuyanLinda Y WuMelanie E SchweitzerDavid J PisapiaOren J BecherMark M SouweidaneUday B Maachani

Published in: Neuro-oncology advances (2019)

Our data indicate that ZSTK474 and trametinib combinatorial treatment inhibits malignant growth of DIPG cells in vitro and in vivo, prolonging survival. These results suggest a promising new combinatorial approach using CED for DIPG therapy, which warrants further investigation.

Keyphrases

induced apoptosis
dendritic cells
cell cycle arrest
stem cells
electronic health record
regulatory t cells
big data
oxidative stress
pi k akt
signaling pathway
machine learning
drug delivery
cell therapy
replacement therapy
type iii